84.81
price up icon0.00%   0.065
 
loading
Alcon Inc stock is traded at $84.81, with a volume of 919.10K. It is up +0.00% in the last 24 hours and down -5.51% over the past month. Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
See More
Previous Close:
$84.88
Open:
$84.82
24h Volume:
919.10K
Relative Volume:
0.55
Market Cap:
$44.00B
Revenue:
$9.93B
Net Income/Loss:
$1.12B
P/E Ratio:
37.70
EPS:
2.25
Net Cash Flow:
$1.58B
1W Performance:
-4.18%
1M Performance:
-5.51%
6M Performance:
+0.17%
1Y Performance:
-4.98%
1-Day Range:
Value
$84.48
$85.31
1-Week Range:
Value
$84.48
$89.45
52-Week Range:
Value
$80.48
$101.10

Alcon Inc Stock (ALC) Company Profile

Name
Name
Alcon Inc
Name
Phone
-
Name
Address
-
Name
Employee
25,599
Name
Twitter
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
ALC's Discussions on Twitter

Compare ALC with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Medical Instruments & Supplies icon
ALC
Alcon Inc
84.86 44.00B 9.93B 1.12B 1.58B 2.25
Medical Instruments & Supplies icon
ISRG
Intuitive Surgical Inc
510.29 189.82B 8.71B 2.48B 1.75B 6.82
Medical Instruments & Supplies icon
BDX
Becton Dickinson Co
169.00 49.98B 20.87B 1.50B 2.59B 5.24
Medical Instruments & Supplies icon
RMD
Resmed Inc
250.80 37.05B 5.02B 1.31B 1.56B 8.91
Medical Instruments & Supplies icon
WST
West Pharmaceutical Services Inc
218.57 16.36B 2.90B 467.20M 306.90M 6.37

Alcon Inc Stock (ALC) Upgrades & Downgrades

Date Action Analyst Rating Change
May-20-25 Downgrade Deutsche Bank Buy → Hold
May-14-25 Reiterated BTIG Research Buy
Mar-28-25 Reiterated Needham Buy
Mar-25-25 Upgrade BofA Securities Neutral → Buy
Jan-24-25 Reiterated Needham Buy
Jan-10-25 Upgrade Redburn Atlantic Neutral → Buy
Dec-17-24 Reiterated Needham Buy
Nov-12-24 Reiterated Needham Buy
Oct-10-24 Upgrade Redburn Atlantic Sell → Neutral
Sep-10-24 Upgrade RBC Capital Mkts Sector Perform → Outperform
Jul-15-24 Upgrade Morgan Stanley Underweight → Equal-Weight
May-15-24 Upgrade Oppenheimer Perform → Outperform
Apr-10-24 Initiated Goldman Buy
Mar-14-24 Initiated RBC Capital Mkts Sector Perform
Feb-06-24 Resumed KeyBanc Capital Markets Overweight
Jan-23-24 Initiated Bernstein Outperform
Dec-18-23 Downgrade Redburn Atlantic Neutral → Sell
Dec-12-23 Initiated Stifel Buy
Dec-04-23 Downgrade Morgan Stanley Equal-Weight → Underweight
Aug-17-23 Upgrade JP Morgan Neutral → Overweight
May-30-23 Resumed Morgan Stanley Equal-Weight
May-10-23 Upgrade Robert W. Baird Neutral → Outperform
Mar-01-23 Upgrade Societe Generale Sell → Hold
Dec-22-22 Initiated Mizuho Buy
Nov-17-22 Downgrade Societe Generale Hold → Sell
Aug-11-22 Downgrade Societe Generale Buy → Hold
May-13-22 Resumed Credit Suisse Outperform
May-12-22 Upgrade Stephens Equal-Weight → Overweight
Apr-08-22 Initiated Needham Buy
Mar-11-22 Initiated BofA Securities Buy
Jan-18-22 Downgrade Stephens Overweight → Equal-Weight
Jan-07-22 Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-01-21 Initiated Oppenheimer Perform
Jul-14-21 Initiated Deutsche Bank Buy
May-06-21 Upgrade Citigroup Sell → Neutral
Mar-22-21 Upgrade BTIG Research Neutral → Buy
Nov-12-20 Downgrade Guggenheim Buy → Neutral
Jul-06-20 Downgrade Citigroup Neutral → Sell
Jul-06-20 Initiated KeyBanc Capital Markets Sector Weight
Jun-16-20 Upgrade Guggenheim Neutral → Buy
Apr-08-20 Downgrade Robert W. Baird Outperform → Neutral
Mar-26-20 Upgrade Argus Hold → Buy
Mar-24-20 Upgrade Societe Generale Sell → Hold
Mar-13-20 Upgrade UBS Neutral → Buy
Mar-05-20 Initiated Citigroup Neutral
Feb-26-20 Upgrade Berenberg Hold → Buy
Jan-08-20 Initiated Argus Hold
Oct-29-19 Initiated Stephens Equal-Weight
Aug-21-19 Reiterated BofA/Merrill Neutral
Jun-24-19 Initiated SVB Leerink Mkt Perform
Jun-14-19 Initiated BTIG Research Neutral
May-10-19 Initiated Robert W. Baird Outperform
May-02-19 Initiated Credit Suisse Outperform
View All

Alcon Inc Stock (ALC) Latest News

pulisher
07:47 AM

Should Weakness in Alcon Inc.'s (VTX:ALC) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials? - simplywall.st

07:47 AM
pulisher
Jun 09, 2025

Alcon Gets First FDA Approval Since Novartis Spinoff - Orange County Business Journal

Jun 09, 2025
pulisher
Jun 09, 2025

Alcon’s Tryptyr Adds Growth, But Valuation Keeps Shares On 'Hold' (NYSE:ALC) - Seeking Alpha

Jun 09, 2025
pulisher
Jun 06, 2025

Alcon Stock Rated Buy by BTIG Following TRYPTYR Approval - MSN

Jun 06, 2025
pulisher
Jun 06, 2025

Phacoemulsification Devices Market Is Booming Worldwide - openPR.com

Jun 06, 2025
pulisher
Jun 05, 2025

Alcon: Achieving UDI Compliance with Veeva RIM - Veeva

Jun 05, 2025
pulisher
Jun 05, 2025

Alcon (ALC) Receives Increased Price Target from Citi | ALC Stoc - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Alcon (ALC) Receives Increased Price Target from Citi | ALC Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Citi more constructive on EU MedTech: Upgrades Demant; Alcon top pick - Investing.com Canada

Jun 05, 2025
pulisher
Jun 05, 2025

Alcon Inc. (ALC)’s TRYPTYR Wins FDA Nod for Dry Eye Disease - MSN

Jun 05, 2025
pulisher
Jun 03, 2025

BofA Securities lowers Alcon stock price target after Q1 results By Investing.com - Investing.com South Africa

Jun 03, 2025
pulisher
Jun 03, 2025

BofA Securities lowers Alcon stock price target after Q1 results - Investing.com Australia

Jun 03, 2025
pulisher
Jun 02, 2025

Refractive Surgery Market Is Booming So Rapidly 2025-2032 - openPR.com

Jun 02, 2025
pulisher
Jun 01, 2025

Alcon up 4% as FDA approves Tryptyr drops for dry eye - MSN

Jun 01, 2025
pulisher
May 30, 2025

Citi maintains Buy on Alcon, price target CHF99 after FDA nod - Investing.com Nigeria

May 30, 2025
pulisher
May 30, 2025

Alcon gains FDA approval of Tryptyr in DED - The Pharma Letter

May 30, 2025
pulisher
May 30, 2025

BTIG maintains Alcon $99 target, upbeat on TRYPTYR launch By Investing.com - Investing.com Canada

May 30, 2025
pulisher
May 30, 2025

Citi maintains Buy on Alcon, price target CHF99 after FDA nod By Investing.com - Investing.com South Africa

May 30, 2025
pulisher
May 29, 2025

FDA Approves Alcon’s Tryptyr for Dry Eye Disease - Managed Healthcare Executive

May 29, 2025
pulisher
May 29, 2025

Alcon Secures First FDA Approval Since Novartis Spin-Off In 2019 - Benzinga

May 29, 2025
pulisher
May 29, 2025

Alcon Stock Rises Following the FDA Approval of TRYPTYR - MSN

May 29, 2025
pulisher
May 29, 2025

US FDA approves Alcon's new dry-eye drug - Reuters

May 29, 2025
pulisher
May 29, 2025

FDA approves Alcon’s Tryptyr (AR-15512) for signs and symptoms of dry eye disease - Ophthalmology Times

May 29, 2025
pulisher
May 29, 2025

Alcon receives FDA approval for Tryptyr to treat dry eye disease - World Pharmaceutical Frontiers

May 29, 2025
pulisher
May 29, 2025

FDA approves Alcon’s TRYPTYR for Dry Eye Disease treatment By Investing.com - Investing.com South Africa

May 29, 2025
pulisher
May 29, 2025

BTIG maintains Alcon $99 target, upbeat on TRYPTYR launch - Investing.com

May 29, 2025
pulisher
May 29, 2025

Alcon’s Strategic Initiatives and Valuation Justify Buy Rating with $99 Price Target - TipRanks

May 29, 2025
pulisher
May 28, 2025

US FDA Approves Alcon's Dry Eye Disease Treatment - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

US FDA approves Alcon’s new dry-eye drug - The Mighty 790 KFGO

May 28, 2025
pulisher
May 28, 2025

Alcon (ALC) Gains FDA Approval for Innovative Dry Eye Treatment - GuruFocus

May 28, 2025
pulisher
May 28, 2025

US FDA approves Alcon's new dry-eye drug (May 28) - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic s - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Alcon (ALC) Gains FDA Nod for Innovative Dry Eye Treatment | ALC Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease | ALC Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

FDA approves Alcon’s TRYPTYR for Dry Eye Disease treatment - Investing.com

May 28, 2025
pulisher
May 28, 2025

Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

Gordon Schanzlin New Vision Institute First in Region to Offer Groundbreaking Alcon Sitemap Technology for Personalized Vision Correction - GlobeNewswire Inc.

May 28, 2025
pulisher
May 28, 2025

BTIG maintains Alcon stock Buy rating, $99 target By Investing.com - Investing.com South Africa

May 28, 2025
pulisher
May 27, 2025

DOJ Requires Keysight to Shed Spirent Units Before $1.57 Billion Acquisition Proceeds - PYMNTS.com

May 27, 2025
pulisher
May 27, 2025

BTIG maintains Alcon stock Buy rating, $99 target - Investing.com

May 27, 2025

Alcon Inc Stock (ALC) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
medical_instruments_supplies BDX
$168.90
price down icon 0.40%
medical_instruments_supplies RMD
$250.41
price up icon 0.23%
medical_instruments_supplies WST
$217.92
price up icon 0.22%
medical_instruments_supplies BAX
$29.75
price down icon 0.29%
$64.32
price up icon 0.29%
Cap:     |  Volume (24h):